Patents by Inventor John H. Wolfe

John H. Wolfe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150374803
    Abstract: The present invention provides AAV vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to subjects.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Inventor: John H. Wolfe
  • Patent number: 8703733
    Abstract: Compositions and methods for treating neurological diseases and disorders are disclosed.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: April 22, 2014
    Assignee: The Children's Hospital of Philadelphia
    Inventors: John H. Wolfe, Carlos Gay-Antaki
  • Publication number: 20130317089
    Abstract: Compositions and methods effective for increasing bladder control are provided.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 28, 2013
    Inventors: John H. Wolfe, Rita Valentino
  • Publication number: 20130143951
    Abstract: Compositions and methods for treating neurological diseases and disorders are disclosed.
    Type: Application
    Filed: May 13, 2011
    Publication date: June 6, 2013
    Applicant: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: John H. Wolfe, Carlos Gay-Antaki
  • Patent number: 7402308
    Abstract: The invention provides a method of delivering a selected DNA sequence to the central nervous system of a mammal by administering to said mammal a neurotropic virus, said virus containing a selected DNA sequence under the control of a promoter which permits expression of the DNA during the latent infectious state of the virus.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: July 22, 2008
    Assignees: Trustees of the University of Pennsylvania, The Wistar Institute
    Inventors: John H. Wolfe, Nigel W. Fraser
  • Publication number: 20040214332
    Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.
    Type: Application
    Filed: December 15, 2003
    Publication date: October 28, 2004
    Applicants: Children's Medical Center Corporation, University of British Columbia, University of Pennsylvania
    Inventors: Snyder Y. Evan, John H. Wolfe, Seung U. Kim
  • Patent number: 6680198
    Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: January 20, 2004
    Assignees: The Children's Medical Center Corporation, University of British Columbia, University of Pennsylvania
    Inventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim
  • Patent number: 6541255
    Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: April 1, 2003
    Assignees: The Children's Medical Center Corporation, The University of British Columbia, The University of Pennsylvania
    Inventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim
  • Patent number: 6528306
    Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: March 4, 2003
    Assignees: The Children's of Medical Center Corporation, The University of British Columbia, The University of Pennsylvania
    Inventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim
  • Patent number: 5958767
    Abstract: Stable clones of neural stem cells (NSCs) have been isolated from the human fetal telencephalon. In vitro, these self-renewing clones (affirmed by retroviral insertion site) can spontaneously give rise to all 3 fundamental neural cell types (neurons, oligodendrocytes, astrocytes). Following transplantation into germinal zones of the developing newborn mouse brain, they, like their rodent counterparts, can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple developmentally- and regionally-appropriate cell types in response to microenvironmental cues, and non-disruptive, non-tumorigenic interspersion with host progenitors and their progeny. Readily genetically engineered prior to transplantation, human NSCs are capable of expressing foreign transgenes in vivo in these disseminated locations.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: September 28, 1999
    Assignee: The Children's Medical Center Corp.
    Inventors: Evan Y. Snyder, John H. Wolfe, Seung U. Kim